Division of Hematology and Oncology, Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
Division of Hematologic Malignancies and Cellular Therapies, Department of Oncology, Albert Einstein College of Medicine, Bronx, New York.
Clin Cancer Res. 2022 Oct 3;28(19):4167-4170. doi: 10.1158/1078-0432.CCR-22-1881.
A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population. See related article by Nagler et al., p. 4258.
相当一部分急性髓系白血病（AML）患者无法缓解。造血干细胞移植（HSCT）是唯一具有长期生存潜力的干预措施。最近急性白血病工作组（ALWP）/欧洲血液和骨髓移植学会（EBMT）的分析报告显示，对于接受移植的活动性疾病患者，移植后有显著的生存获益。复发减少是生存的最大贡献因素，这为这一具有挑战性的人群带来了乐观的理由。见 Nagler 等人的相关文章，第 4258 页。
